Nanoparticle-Based Treatment in Glioblastoma

Area of Science:

• Neuro-oncology
• Nanomedicine
• Drug Delivery Systems

Background:

• Glioblastoma (GB) has a poor prognosis with a median survival of 12-18 months, characterized by high relapse rates and treatment resistance.
• Standard treatment involves surgery, radiotherapy, and chemotherapy, but drug efficacy is limited by the blood-brain barrier (BBB).

Purpose of the Study:

• To review recent literature on nanoparticle-based therapies for glioblastoma treatment.
• To highlight the potential of polymeric nanoparticles in overcoming BBB limitations for improved glioblastoma therapy.

Main Methods:

• Review of pre-clinical studies focusing on polymeric nanoparticles for glioblastoma treatment.
• Analysis of nanoparticle strategies designed to cross the BBB and enhance drug delivery to the brain.

Main Results:

• Polymeric nanoparticles demonstrate potential for targeted brain drug delivery, minimizing systemic toxicity and degradation.
• Various nanoparticle-based drug delivery methods are under investigation in vitro and in vivo.
• Few nanoparticle systems have progressed to clinical trials, emphasizing the importance of pre-clinical research.

Conclusions:

• Nanoparticle-based treatments, particularly polymeric nanoparticles, offer a promising avenue for improving glioblastoma patient outcomes.
• Continued pre-clinical research is essential to validate the safety and efficacy of these novel therapies before clinical application.